VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
| Revenue (Most Recent Fiscal Year) | $0.49M |
| Net Income (Most Recent Fiscal Year) | $-51.42M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.45 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -8486.84% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -109.72% |
| Return on Assets (Trailing 12 Months) | -89.62% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.67 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.67 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.44 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.45 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.67 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.89 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 39.62M |
| Free Float | 38.49M |
| Market Capitalization | $23.24M |
| Average Volume (Last 20 Days) | 0.45M |
| Beta (Past 60 Months) | 0.33 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.85% |
| Percentage Held By Institutions (Latest 13F Reports) | 78.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |